Skip to Main Content

Paper Details

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia.
J Clin Med
2
2023
Author NameAffiliation
Maria MazzitelliUniversity Hospital of Padua
  • 1 - 1

Datasets

Release 1.2